全文获取类型
收费全文 | 2074篇 |
免费 | 16篇 |
国内免费 | 2篇 |
专业分类
电工技术 | 7篇 |
综合类 | 52篇 |
化学工业 | 85篇 |
金属工艺 | 5篇 |
机械仪表 | 26篇 |
建筑科学 | 50篇 |
矿业工程 | 2篇 |
能源动力 | 8篇 |
轻工业 | 38篇 |
水利工程 | 9篇 |
石油天然气 | 1篇 |
无线电 | 61篇 |
一般工业技术 | 107篇 |
冶金工业 | 1554篇 |
自动化技术 | 87篇 |
出版年
2021年 | 3篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 6篇 |
2015年 | 16篇 |
2014年 | 24篇 |
2013年 | 39篇 |
2012年 | 36篇 |
2011年 | 38篇 |
2010年 | 26篇 |
2009年 | 25篇 |
2008年 | 32篇 |
2007年 | 26篇 |
2006年 | 13篇 |
2005年 | 12篇 |
2004年 | 19篇 |
2003年 | 22篇 |
2002年 | 8篇 |
2001年 | 18篇 |
2000年 | 9篇 |
1999年 | 50篇 |
1998年 | 443篇 |
1997年 | 263篇 |
1996年 | 168篇 |
1995年 | 127篇 |
1994年 | 102篇 |
1993年 | 105篇 |
1992年 | 15篇 |
1991年 | 28篇 |
1990年 | 30篇 |
1989年 | 33篇 |
1988年 | 28篇 |
1987年 | 29篇 |
1986年 | 19篇 |
1985年 | 17篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 14篇 |
1981年 | 11篇 |
1980年 | 11篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1977年 | 35篇 |
1976年 | 96篇 |
1975年 | 7篇 |
1974年 | 7篇 |
1971年 | 3篇 |
1926年 | 3篇 |
排序方式: 共有2092条查询结果,搜索用时 15 毫秒
81.
82.
83.
84.
The crying infant is a common presenting complaint and a difficult diagnostic dilemma that may represent the primary manifestation of a serious or even life-threatening condition. Although many children experience an exacerbation of the normal crying tendencies or minor ailments typical of the early months of life, a significant number of infants have underlying pathologic conditions requiring immediate intervention. This article briefly reviews current and past research on this phenomenon and presents differential diagnoses and recommendations for the evaluation and management of the acute crying episode. 相似文献
85.
86.
87.
88.
DC Underwood S Bochnowicz RR Osborn CJ Kotzer MA Luttmann DW Hay PD Gorycki SB Christensen TJ Torphy 《Canadian Metallurgical Quarterly》1998,287(3):988-995
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy-4-methoxyp henyl-r-1-cyclohexane carboxylic acid)], in the guinea pig. Ovalbumin (OA)-induced contractions of guinea pig isolated tracheal strips were inhibited by SB 207499 with an EC50 of 1 microM but had little or no effect on exogenous agonist-induced contraction, which suggests that its effect on OA-induced contraction in vitro is primarily due to inhibition of mediator release from mast cells. In anesthetized guinea pigs, SB 207499 inhibited OA-induced bronchoconstriction with i.v. and p.o. ID50 values of 1.7 and 17 mg/kg, respectively. At 1, 3 and 6 hr after SB 207499 (30 mg/kg p.o.), OA-induced bronchospasm was inhibited by 92%, 70% and 58%, respectively, corresponding to elevated plasma concentrations of 1.62 +/- 0.19, 1.65 +/- 0.29 and 0. 93 +/- 0.24 microg/ml, respectively, of SB 207499. SB 207499 also inhibited house dust mite-induced bronchoconstriction (ID50 = 0.9 mg/kg i.v. and 8.9 mg/kg p.o.). In contrast to its lack of bronchorelaxant activity in vitro, SB 207499 inhibited bronchospasm induced by i.v. leukotriene D4 (LTD4) [ID50 = 3 mg/kg i.v.]. The bronchorelaxant effect of i.v.-administered SB 207499 was at least additive with that of salbutamol in reversing infused histamine-enhanced airway tone, but it did not alter base line or enhance salbutamol-induced cardiovascular effects. In conscious guinea pigs, SB 207499 (10 or 30 mg/kg p.o.), 1 hr before antigen or LTD4 challenge, markedly reduced bronchospasm and subsequent eosinophil influx as measured by bronchoalveolar lavage 24 hr after provocation. SB 207499 administered after OA or LTD4 challenge also reduced airway eosinophilia measured at 24 hr after OA challenge or 96 hr after LTD4 challenge. These results, coupled with the broad anti-inflammatory activity of SB 207499 previously described (Barnett et al., 1998), suggest that SB 207499 will be useful in the treatment of asthma and other inflammatory disorders. 相似文献
89.
MD de Jong GJ Galasso B Gazzard PD Griffiths DA Jabs ER Kern SA Spector 《Canadian Metallurgical Quarterly》1998,39(3):141-162
Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. 相似文献
90.
IM Bell JM Erb RM Freidinger SN Gallicchio JP Guare MT Guidotti RA Halpin DW Hobbs CF Homnick MS Kuo EV Lis DJ Mathre SR Michelson JM Pawluczyk DJ Pettibone DR Reiss S Vickers PD Williams CJ Woyden 《Canadian Metallurgical Quarterly》1998,41(12):2146-2163
The previously reported oxytocin antagonist L-371,257 (2) has been modified at its acetylpiperidine terminus to incorporate various pyridine N-oxide groups. This modification has led to the identification of compounds with improved pharmacokinetics and excellent oral bioavailability. The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors. Incorporation of a 5-fluoro substituent on the central benzoyl ring of this class of oxytocin antagonists enhanced in vitro and in vivo potency but was detrimental to the pharmacokinetic profiles of these compounds. Although lipophilic substitution around the pyridine ring of compound 30 gave higher affinity in vitro, such substituents were a metabolic liability and caused shortfalls in vivo. Two approaches to prevent this metabolism, addition of a cyclic constraint and incorporation of trifluoromethyl groups, were examined. The former approach was ineffective because of metabolic hydroxylation on the constrained ring system, whereas the latter showed improvement in plasma pharmacokinetics in some cases. 相似文献